A single-center, prospective, single-arm, phase II trial to evaluate the adjuvant efficacy of camrelizumab with docetaxel plus S-1 for stage III (PD-L1(+)/dMMR/EBV+) gastric cancer after D2 resection
JOURNAL OF CLINICAL ONCOLOGY（2023）
关键词
gastric cancer,camrelizumab,adjuvant efficacy,docetaxel,single-center,single-arm
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要